AR121961A1 - Inmunoterapia con citocina - Google Patents
Inmunoterapia con citocinaInfo
- Publication number
- AR121961A1 AR121961A1 ARP210101153A ARP210101153A AR121961A1 AR 121961 A1 AR121961 A1 AR 121961A1 AR P210101153 A ARP210101153 A AR P210101153A AR P210101153 A ARP210101153 A AR P210101153A AR 121961 A1 AR121961 A1 AR 121961A1
- Authority
- AR
- Argentina
- Prior art keywords
- cytocin
- immunotherapy
- alphavirus
- cytosine
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente memoria se proporciona un nuevo vector replicón de alfavirus inmunológicamente activo que comprende un ácido nucleico que codifica las proteínas no estructurales de alfavirus nsp1-4 y una proteína / polipéptido de citosina, que es útil para el tratamiento de un cáncer y/o una enfermedad inflamatoria.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063017993P | 2020-04-30 | 2020-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121961A1 true AR121961A1 (es) | 2022-07-27 |
Family
ID=78292585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101153A AR121961A1 (es) | 2020-04-30 | 2021-04-29 | Inmunoterapia con citocina |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210340567A1 (es) |
EP (1) | EP4143323A1 (es) |
JP (1) | JP2023524055A (es) |
KR (1) | KR20230005883A (es) |
CN (1) | CN115552009A (es) |
AR (1) | AR121961A1 (es) |
AU (1) | AU2021264216A1 (es) |
BR (1) | BR112022021828A2 (es) |
CA (1) | CA3174651A1 (es) |
IL (1) | IL297564A (es) |
MX (1) | MX2022013638A (es) |
TW (1) | TW202206448A (es) |
WO (1) | WO2021221127A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024086619A2 (en) * | 2022-10-19 | 2024-04-25 | Kalivir Immunotherapeutics, Inc. | Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2668417A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
EP3197911A4 (en) * | 2014-09-22 | 2018-06-20 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
US11421010B2 (en) * | 2016-10-07 | 2022-08-23 | Board Of Regents, The University Of Texas System | T cells expressing membrane-anchored IL-12 for the treatment of cancer |
AU2018270111B2 (en) * | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
EP3728611A4 (en) * | 2017-12-20 | 2021-09-08 | VLP Therapeutics, Inc. | ALPHAVIRUS REPLICON PARTICLES |
-
2021
- 2021-04-28 EP EP21797719.8A patent/EP4143323A1/en active Pending
- 2021-04-28 KR KR1020227040275A patent/KR20230005883A/ko unknown
- 2021-04-28 CN CN202180031708.1A patent/CN115552009A/zh active Pending
- 2021-04-28 IL IL297564A patent/IL297564A/en unknown
- 2021-04-28 MX MX2022013638A patent/MX2022013638A/es unknown
- 2021-04-28 JP JP2022566180A patent/JP2023524055A/ja active Pending
- 2021-04-28 AU AU2021264216A patent/AU2021264216A1/en active Pending
- 2021-04-28 WO PCT/JP2021/017078 patent/WO2021221127A1/en unknown
- 2021-04-28 BR BR112022021828A patent/BR112022021828A2/pt unknown
- 2021-04-28 CA CA3174651A patent/CA3174651A1/en active Pending
- 2021-04-28 US US17/242,916 patent/US20210340567A1/en active Pending
- 2021-04-29 TW TW110115598A patent/TW202206448A/zh unknown
- 2021-04-29 AR ARP210101153A patent/AR121961A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023524055A (ja) | 2023-06-08 |
US20210340567A1 (en) | 2021-11-04 |
EP4143323A1 (en) | 2023-03-08 |
IL297564A (en) | 2022-12-01 |
WO2021221127A1 (en) | 2021-11-04 |
KR20230005883A (ko) | 2023-01-10 |
TW202206448A (zh) | 2022-02-16 |
CA3174651A1 (en) | 2021-11-04 |
MX2022013638A (es) | 2023-01-24 |
CN115552009A (zh) | 2022-12-30 |
AU2021264216A1 (en) | 2022-11-10 |
BR112022021828A2 (pt) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17059343A (es) | ARNi VARIANTE | |
CL2021000997A1 (es) | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno. | |
PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
CO2018004564A2 (es) | Genes de ataxia de friedreich modificados y vectores para terapia génica | |
UY36304A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
CY1117423T1 (el) | Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
CY1115341T1 (el) | Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων | |
AR110567A1 (es) | Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina) | |
EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
CO2021007916A2 (es) | Ácido ribonucleico (arn) que codifica para una proteína | |
EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
CO2021008995A2 (es) | Proteínas de unión multiespecíficas con dominios fab mutantes | |
PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
BR112017004393A2 (pt) | formulações de anticorpo | |
AR121961A1 (es) | Inmunoterapia con citocina | |
CL2020002650A1 (es) | Enzimas quinureninasa humanas y sus usos | |
BR112022006842A2 (pt) | Construtos de igf2 variante | |
AR119271A1 (es) | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada | |
CL2018002900A1 (es) | Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos. |